View profile

FarmaKology Newsletter - Issue #35

Would you like to submit an article, some interesting news, or get your startup featured? Send whatev


February 26 · Issue #35 · View online
FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to, and happy to have you featured on our newsletter (+3000 Subscribers ) !

Today's Startup
Healx is an AI-powered and patient-inspired technology company, accelerating the discovery and development of rare disease treatments. Our AI drug discovery platform leverages public and proprietary biomedical data and features the world’s leading knowledge graph for rare diseases. Combining this technology with patient insights and drug discovery expertise, our mission is to advance 100 rare disease treatments towards the clinic by 2025.
Biopharma company Atrin Pharmaceuticals, a drug discovery and development company focused on molecules targeting DNA damage and repair pathways to treat cancer, and gene-based analytics company Predictive Technology Group say they have successfully tested a collaborative genomics analysis for more accurate clinical trial screening for ATRN-119, an ATR inhibitor with therapeutic potential across a broad range of cancers. The company anticipates initiating first-in-human trials this year.
Researchers at Harvard University and the Guangzhou Institute of Respiratory Health in China will partner to develop therapies designed to prevent new Coronavirus infections and treat existing ones, through a $115 million research collaboration funded by Chinese real estate giant China Evergrande Group.
POINT Biopharma, a newly formed pharmaceutical company, is combining a seasoned management team with strategic partnerships in radio-isotope supply, manufacturing technology and novel direct to patient targeting to revolutionize radiopharmaceutical drug development and commercialization.
Noxopharm announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug application for Veyonda® for combination treatment with doxorubicin in patients with soft tissue sarcomas.
Research & Study
Helping Biosimilars Emerge into Global Markets Takes a Practiced Hand by GEN Podcasts | Free Listening on SoundCloud
Job Opportunities
Upcoming Events
Why labs are printing the coronavirus genome
Did you enjoy this issue?
If you don't want these updates anymore, please unsubscribe here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue